A spectrum of lung cancer-derived EGFR mutations can induce oncogenic transformation by leading to constitutive kinase activity and confer markedly different degrees of sensitivity to EGFR inhibitors [45]–[47]. The gene discussed is EGFR; the disease is lung cancer.